Dr Reddy's Laboratories Launches Lamotrigine Orally Disintegrating Tablets in US Market
Hyderabad : Dr. Reddy’s Laboratories Ltd.announced that it has launched Lamotrigine Orally Disintegrating Tablets in 25 mg, 50 mg, 100 mg, and 200 mg, a therapeutic equivalent generic version of Lamictal® ODT (lamotrigine) Orally Disintegrating Tablets in the United States market approved by the U.S. Food & Drug Administration (USFDA).
The Lamictal® ODT brand and generic had U.S. sales of approximately $65.5 million MAT for the most recent twelve months ending in July 2016 according to IMS Health*.
Dr. Reddy’s Lamotrigine Orally Disintegrating Tablets 25 mg, 50 mg, 100 mg, and 200 mg are available in bottle count sizes of 30s.
Lamictal® ODT is a registered trademark of GSK group of companies.
*IMS National Sales Perspective: Retail and Non-Retail MAT July 2016